valproic acid has been researched along with hydralazine in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (31.25) | 29.6817 |
| 2010's | 22 (68.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Arce, C; Bargallo, E; Camargo, MF; Candelaria, M; Chávez-Blanco, A; de la Cruz-Hernández, E; Dueñas-González, A; González-Fierro, A; Pérez-Cárdenas, E; Pérez-Plasencia, C; Ramírez, T; Revilla-Vázquez, A; Robles, E; Taja-Chayeb, L; Trejo-Becerril, C; Vela, T; Villarreal, P | 1 |
| Cantú, D; Contreras-Paredes, A; de la Cruz-Hernández, E; Dueñas-González, A; Lizano, M; Mohar, A; Pérez-Cárdenas, E | 1 |
| Aguilar-Ponce, JL; Arce, C; Arrieta, O; Camargo, MF; Candelaria, M; Cetina, L; Chávez-Blanco, A; de la Cruz-Hernández, E; Dueñas-González, A; Gallardo-Rincón, D; González-Fierro, A; Pérez-Cárdenas, E; Pérez-Plasencia, C; Revilla-Vazquez, A; Taja-Chayeb, L; Trejo-Becerril, C; Wegman-Ostrosky, T | 1 |
| Bartholome, R; Baumann, M; Janssen, BJ; Rob Hermans, JJ; Smits, JF; Struijker Boudier, HA | 1 |
| Cardinale, JP; Elks, CM; Francis, J; Guggilam, A; Mariappan, N; Pariaut, R; Sriramula, S | 1 |
| Arias, D; Candelaria, M; Cetina, L; Chanona, J; de la Cruz-Hernández, E; Dueñas-González, A; González-Fierro, A; Pérez-Cárdenas, E; Taja-Chayeb, L; Trejo-Becerril, C | 1 |
| Arias-Bofill, D; Candelaria, M; Cervera, E; de la Cruz-Hernández, E; Dueñas-Gonzalez, A; González-Fierro, A; Herrera, A; Labardini, J; Pérez-Cárdenas, E; Taja-Chayeb, L; Trejo-Becerril, C; Vidal, S | 1 |
| Arias-Bofill, D; Candelaria, M; Cetina, L; Coronel, J; de la Cruz-Hernandez, E; Dueñas-González, A; González-Fierro, A; Pacheco, I; Perez-Cardenas, E; Taja-Chayeb, L; Trejo-Becerril, C; Vidal, S | 1 |
| Chávez-Blanco, A; De la Cruz-Hernández, E; Dominguez, GI; Duenas-González, A; Gonzalez-Fierro, A; Gutiérrez, O; Pérez-Cardenas, E; Perez-Plasencia, C; Taja-Chayeb, L; Trejo-Becerril, C; Trujillo, JE; Vidal, S | 1 |
| Alatorre, B; Chacón-Salinas, R; Chávez-Blanco, A; Contreras-Paredes, A; De la Cruz-Hernández, E; Domínguez, GI; Dueñas-González, A; Pérez-Cárdenas, E; Rodríguez-Cortez, O; Taja-Chayeb, L; Trejo-Becerril, C; Trujillo, JE | 1 |
| Candelaria, M; Cervera, E; Cortes, J; Dueñas-González, A; Gonzalez-Fierro, A; Gordillo-Bastidas, D; Labardini, J; López-Navarro, O; Taja-Chayeb, L | 1 |
| Chiaratti, MR; de Araújo, RR; De Bem, TH; Meirelles, FV; Oliveira, Lde J; Perecin, F; Sangalli, JR; Smith, LC; Valim Pimentel, JR | 1 |
| Fukunaga, S; Futani, H; Hata, M; Kato-Kogoe, N; Kobayashi, K; Nakasho, K; Ohyama, H; Okamura, H; Terada, N; Yamada, N; Yamane, J; Yamanegi, K | 1 |
| Cedillo-Carvallo, B; Dueñas-González, A; Estrada-Marín, L; Garcés-Eisele, SJ; Guzmán-García, MO; Juárez-Calderón, M; Reyes-Núñez, V; Ruiz-Argüelles, A; Vázquez-Pérez, R | 1 |
| Dueñas-González, A; Isaac-Olivé, K; Mani, E; Medina, LA | 1 |
| Cetina, L; Chavez-Blanco, A; Coronel, J; Dueñas-Gonzalez, A; González-Fierro, A; Taja-Chayeb, L | 1 |
| Carter, CA; Day, RM; Lybeck, M; Oronsky, A; Oronsky, B; Oronsky, N; Richard, P; Scicinski, J; Zeman, K | 1 |
| Bouker, KB; Clarke, R; Cook, KL; Cruz, MI; de Assis, S; Hilakivi-Clarke, L; Hu, R; Jin, L; Nguyen, N; Wang, X; Wang, Y; Wärri, A; Wehrenberg, B; Xuan, J; Zhang, X; Zwart, A | 1 |
| Candelaria, M; Cervera, E; Dueñas-González, A; Espinoza-Zamora, JR; Labardini-Méndez, J; López-González, C; Lozano-Zavaleta, V; Sosa-Espinoza, A; Toledano-Cuevas, DV; Vieyra-García, M; Zapata-Canto, N | 1 |
| Burgos, S; Candelaria, M; Dueñas-Gonzalez, A; Espinoza, R; Ponce, M | 1 |
| Fujihara, Y; Futani, H; Kobayashi, K; Kumanishi, S; Nakasho, K; Nishiura, H; Yamanegi, K; Yoshiya, S | 1 |
| Andrade, FO; Hilakivi-Clarke, L; Nguyen, NM; Warri, A | 1 |
3 review(s) available for valproic acid and hydralazine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; DNA Methylation; Drug Repositioning; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Hydralazine; Neoplasms; Valproic Acid | 2014 |
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.
Topics: Antibodies, Monoclonal; Azacitidine; Azetidines; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; CpG Islands; Disease Progression; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Histones; Humans; Hydralazine; Immunotherapy; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Recurrence, Local; Nitro Compounds; Nivolumab; Prognosis; Pyridines; Treatment Outcome; Valproic Acid | 2016 |
7 trial(s) available for valproic acid and hydralazine
| Article | Year |
|---|---|
A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; DNA Methylation; Doxorubicin; Epigenesis, Genetic; Female; Gene Expression; Histone Deacetylase Inhibitors; Humans; Hydralazine; Middle Aged; Neoadjuvant Therapy; Valproic Acid | 2006 |
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Histone Deacetylases; Humans; Hydralazine; Male; Neoplasms; Valproic Acid | 2007 |
Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial.
Topics: Adult; Aged; Azacitidine; Cytogenetic Analysis; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Modification Methylases; Epigenomics; Female; Histone Deacetylase Inhibitors; Humans; Hydralazine; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome; Valproic Acid; Young Adult | 2011 |
A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Double-Blind Method; Epigenesis, Genetic; Female; Follow-Up Studies; Genetic Therapy; Humans; Hydralazine; Middle Aged; Survival Rate; Uterine Cervical Neoplasms; Valproic Acid | 2011 |
Treatment of nuclear-donor cells or cloned zygotes with chromatin-modifying agents increases histone acetylation but does not improve full-term development of cloned cattle.
Topics: Acetylation; Animals; Azacitidine; Cattle; Cell Nucleus; Cells, Cultured; Chromatin Assembly and Disassembly; Cloning, Organism; Decitabine; Embryonic Development; Female; Histone Deacetylase Inhibitors; Histones; Hydralazine; Hydroxamic Acids; Nuclear Transfer Techniques; Pregnancy; Term Birth; Up-Regulation; Valproic Acid; Zygote | 2012 |
Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure.
Topics: Acetylation; Adult; Area Under Curve; Arylamine N-Acetyltransferase; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Genotype; Humans; Hydralazine; Male; Mexico; Middle Aged; Pilot Projects; Polymorphism, Single Nucleotide; Tablets; Tandem Mass Spectrometry; Valproic Acid; Young Adult | 2014 |
Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hydralazine; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Pruritus; Survival Rate; Time Factors; Treatment Outcome; Valproic Acid; Young Adult | 2017 |
22 other study(ies) available for valproic acid and hydralazine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study.
Topics: Acetylation; Alphapapillomavirus; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Enzyme Inhibitors; Female; Gene Expression; Gene Expression Regulation, Viral; Genes, p53; Histone Deacetylase Inhibitors; Histones; Humans; Hydralazine; Oncogene Proteins, Viral; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger; Transcription, Genetic; Tumor Suppressor Protein p53; Uterine Cervical Neoplasms; Valproic Acid | 2007 |
Renal medullary effects of transient prehypertensive treatment in young spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Apoptosis; Blood Pressure; Cysteine Proteinase Inhibitors; Drug Therapy, Combination; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hydralazine; Hypertension; Kidney Medulla; Losartan; Male; Oligopeptides; Osmolar Concentration; Pericytes; Phosphorylation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renal Circulation; Sodium; Urine; Valproic Acid | 2009 |
HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Echocardiography; Histone Deacetylase Inhibitors; Histone Deacetylases; Hydralazine; Hypertension; Immunohistochemistry; Inflammation; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Valproic Acid | 2010 |
Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Brachytherapy; Cisplatin; Combined Modality Therapy; Epigenesis, Genetic; Female; Humans; Hydralazine; Middle Aged; Neoplasm Staging; Uterine Cervical Neoplasms; Valproic Acid | 2010 |
Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydralazine; Microarray Analysis; Transcription, Genetic; Up-Regulation; Uterine Cervical Neoplasms; Valproic Acid | 2011 |
Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytotoxicity, Immunologic; Histocompatibility Antigens Class I; Humans; Hydralazine; Killer Cells, Natural; Ligands; Neoplasms; NK Cell Lectin-Like Receptor Subfamily K; Protein Binding; Up-Regulation; Valproic Acid | 2011 |
Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Follow-Up Studies; Humans; Hydralazine; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome; Valproic Acid | 2012 |
Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas- and NK cell-mediated cell death.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytotoxicity, Immunologic; DNA Methylation; DNA Modification Methylases; Drug Synergism; fas Receptor; Histocompatibility Antigens Class I; Histone Deacetylase Inhibitors; Humans; Hydralazine; Killer Cells, Natural; Osteosarcoma; Promoter Regions, Genetic; Tumor Escape; Valproic Acid | 2012 |
Radiosensitization of cervical cancer cells with epigenetic drugs hydralazine and valproate.
Topics: Cell Line, Tumor; Cell Survival; Combined Modality Therapy; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Female; Histone Deacetylase Inhibitors; Humans; Hydralazine; Radiation-Sensitizing Agents; Radiotherapy; Uterine Cervical Neoplasms; Valproic Acid | 2014 |
Effects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen Resistance and Breast Cancer Recurrence in a Preclinical Model.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenovirus E1A Proteins; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; DNA Methylation; Drug Resistance, Neoplasm; Ethinyl Estradiol; Female; Galectin 3; Gene Expression; Gene Silencing; Histocompatibility Antigens Class I; Humans; Hydralazine; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Mammary Neoplasms, Experimental; Neoplasm Recurrence, Local; Pregnancy; Prenatal Exposure Delayed Effects; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ets; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Tamoxifen; Trans-Activators; Valproic Acid | 2017 |
Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Compassionate Use Trials; Epigenesis, Genetic; Female; Humans; Hydralazine; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Treatment Outcome; Valproic Acid; Young Adult | 2017 |
Epigenetic modulators hydralazine and sodium valproate act synergistically in VEGI-mediated anti-angiogenesis and VEGF interference in human osteosarcoma and vascular endothelial cells.
Topics: Bone Neoplasms; Cell Line; Cell Line, Tumor; Drug Synergism; Endothelial Cells; Enzyme Inhibitors; Epigenesis, Genetic; Humans; Hydralazine; Neovascularization, Pathologic; Osteosarcoma; Receptors, Tumor Necrosis Factor, Member 25; RNA, Messenger; Transcription, Genetic; Tumor Necrosis Factor Ligand Superfamily Member 15; Valproic Acid; Vascular Endothelial Growth Factor A | 2019 |
Reversal of increased mammary tumorigenesis by valproic acid and hydralazine in offspring of dams fed high fat diet during pregnancy.
Topics: Animals; Cell Transformation, Neoplastic; CpG Islands; Cyclin-Dependent Kinase Inhibitor p16; Diet, High-Fat; Disease Susceptibility; DNA Methylation; Female; Hydralazine; Mammary Neoplasms, Animal; Mammary Neoplasms, Experimental; Maternal Exposure; Mice; Pregnancy; Prenatal Exposure Delayed Effects; Tumor Burden; Valproic Acid | 2019 |